Panel Disdussion

3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of
Congress of Nuclear Medicine
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011
NON-FDG PET TRACERS IN ONCOLOGY
Mohsen Farsad (Italy)
Nuclear Medicine Department, PET Unit, Policlinico S. Orsola-Malpighi, Bologna
Educational Objectives:
To delineate the appropriate clinical indications
To help the imaging specialists to interpret correctly the images,
avoiding pitfalls
To get an insight on current status and future perspectives of NON
FDG PET tracers
Summery:
[(18)F]-fluoro-2-deoxy-D-glucose (FDG) is the most frequently used
radiopharmaceutical for clinical positron emission tomography (PET).
However, FDG cannot be used for all cancer types, either because the
abnormal tissue does not concentrate it, or because the tissues under
investigation demonstrate high physiological glucose uptake.
Consequently, alternative PET tracers have been produced and
introduced into clinical practice. The most important NON FDG
compounds in routine practice are 11 C-choline and 18 F-choline, mainly
for the evaluation of prostate cancer; 11 C-methionine and 18 F-FET for
brain tumours;
18 F-DOPA and
68 Ga-DOTA-PEPTIDES for
neuroendocrine tumours. The lecture will highlight the major clinical
applications of the above mentioned PET tracers in Oncology.
Key Words: 11 C-choline; 18 F-choline; 18 F-DOPA; 11 C-methionine;
18 F-FET; 68 Ga-DOTA-NOC; 68 Ga-DOTA-TOC; PET-CT Imaging
35